Edgewise Therapeutics reported earnings of $ 9.65 per EWTX share on Nov 5, 2026, falling short of analysts' expectations by
| Report Date | Nov 5, 2026 |
|---|---|
| Forecasted EPS | -$ 0.52 |
| Earnings Per Share (Surprise) | $ 9.65 (+$ 10.17) |
| Last Year's EPS | -$ 0.41 |
| EPS YoY Change |
Out of the last 28 earnings reporting periods, Edgewise Therapeutics beat analysts’ expectations 15 times and fell short of expectations 9 time(s). Edgewise Therapeutics reported earnings per share of $ 9.65 in the last report surpassing an estimated EPS of -$ 0.52 by
| Report Date | Forecasted EPS | Reported EPS | Last Year's EPS | EPS YoY Change |
|---|---|---|---|---|
| Nov 5, 2026 | -$ 0.52 | $ 9.65 | -$ 0.47 | |
| Nov 4, 2026 | -$ 0.53 | $ 9.65 | -$ 0.39 | |
| Aug 6, 2026 | -$ 0.47 | -$ 0.53 | -$ 0.34 | |
| May 7, 2026 | -$ 0.50 | -$ 0.46 | -$ 0.43 | |
| Feb 26, 2026 | -$ 0.43 | -$ 0.47 | -$ 0.42 | |
| Nov 6, 2025 | -$ 0.40 | -$ 0.39 | -$ 0.36 | |
| Aug 7, 2025 | -$ 0.42 | -$ 0.34 | -$ 0.34 | |
| May 8, 2025 | -$ 0.45 | -$ 0.43 | -$ 0.33 | |
| Mar 3, 2025 | -$ 0.39 | -$ 0.42 | -$ 0.47 | |
| Nov 7, 2024 | -$ 0.37 | -$ 0.36 | -$ 0.41 | |
| Aug 8, 2024 | -$ 0.36 | -$ 0.34 | -$ 0.34 | |
| May 9, 2024 | -$ 0.39 | -$ 0.33 | -$ 0.36 | |
| Feb 22, 2024 | -$ 0.44 | -$ 0.47 | -$ 0.31 | |
| Nov 9, 2023 | -$ 0.40 | -$ 0.41 | -$ 0.34 | |
| Aug 10, 2023 | -$ 0.41 | -$ 0.34 | -$ 0.32 | |
| May 11, 2023 | -$ 0.37 | -$ 0.36 | -$ 0.30 | |
| Feb 23, 2023 | -$ 0.36 | -$ 0.31 | -$ 0.26 | |
| Nov 3, 2022 | -$ 0.36 | -$ 0.34 | -$ 0.26 | |
| Aug 4, 2022 | -$ 0.34 | -$ 0.32 | -$ 0.21 | |
| May 11, 2022 | -$ 0.29 | -$ 0.30 | -$ 4.37 |
Edgewise Therapeutics’s stock was trading at $ 37.53 on Nov 4, 2026 a day before the last earnings report was released.Following the release of the earnings report, EWTX’s price increased to $ 45.04 on Nov 6, 2026, recording a
| Report Date | EPS | Price 1 Day Before | Price 1 Day After | Change |
|---|---|---|---|---|
| Nov 5, 2026 | $ 9.65 | $ 37.53 | $ 45.04 | |
| Nov 4, 2026 | $ 9.65 | $ 37.68 | $ 38.87 | |
| Aug 6, 2026 | -$ 0.53 | $ 44.99 | $ 43.52 | |
| May 7, 2026 | -$ 0.46 | $ 36.99 | $ 35.32 | |
| Feb 26, 2026 | -$ 0.47 | $ 30.12 | $ 30.44 | |
| Nov 6, 2025 | -$ 0.39 | $ 17.37 | $ 17.16 | |
| Aug 7, 2025 | -$ 0.34 | $ 13.52 | $ 12.68 | |
| May 8, 2025 | -$ 0.43 | $ 14.52 | $ 14.58 | |
| Mar 3, 2025 | -$ 0.42 | $ 26.17 | $ 24.50 | |
| Nov 7, 2024 | -$ 0.36 | $ 36.62 | $ 36.38 | |
| Aug 8, 2024 | -$ 0.34 | $ 15.88 | $ 16.45 | |
| May 9, 2024 | -$ 0.33 | $ 20.89 | $ 18.33 | |
| Feb 22, 2024 | -$ 0.47 | $ 17.50 | $ 17.28 | |
| Nov 9, 2023 | -$ 0.41 | $ 6.17 | $ 5.51 | |
| Aug 10, 2023 | -$ 0.34 | $ 6.49 | $ 6.71 | |
| May 11, 2023 | -$ 0.36 | $ 9.91 | $ 9.27 | |
| Feb 23, 2023 | -$ 0.31 | $ 9.86 | $ 9.56 | |
| Nov 3, 2022 | -$ 0.34 | $ 9.40 | $ 9.57 | |
| Aug 4, 2022 | -$ 0.32 | $ 9.20 | $ 10.67 | |
| May 11, 2022 | -$ 0.30 | $ 7.35 | $ 7.47 |
Edgewise Therapeutics released its most recent earnings reports in November 2026, November 2026, August 2026, May 2026 respectively. Generally, most companies have a consistent schedule for their earnings releases. However, companies do not necessarily release their earnings reports at the same time each year. The timing of earnings releases can vary depending on a company's fiscal year, industry norms, and internal reporting practices.
Edgewise Therapeutics beat analysts’ expectations during the last earnings period by
